October 2026
M	T	W	T	F	S	S
	1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Richard Davis: Navigating Acute PE – ESC vs. the New AHA/ACC Guidelines

Richard Davis/LinkedIn

Aug 29, 2026, 11:03

Richard Davis: Navigating Acute PE – ESC vs. the New AHA/ACC Guidelines

Richard Davis, Field Clinical Specialist at Stryker, shared a post on LinkedIn:

“Navigating Acute PE: ESC vs. the New AHA/ACC Guidelines

When managing Acute Pulmonary Embolism, how we stratify risk dictates how we treat.

With the landmark 2026 AHA/ACC Multisociety PE Guidelines now shaping practice, how do they stack up against the traditional European Society of Cardiology (ESC) framework?

Here are the key differences clinicians need to know:

Risk Architecture:

ESC: Relies on a classic 3-tier model (Low, Intermediate, High).
AHA/ACC: Introduces a granular 5-tier alphabetical system (Categories A–E).

Goodbye Vague Terminology:

The AHA/ACC framework officially replaces older, ambiguous terms like “massive” and “submassive” with precise A–E clinical categories to standardize care.

Anatomy vs. Physiology:

While older models heavily factored in anatomical clot burden, the updated AHA/ACC guidelines firmly anchor decisions to cardiopulmonary physiology and right ventricular (RV) function as the primary driver for intervention.

Managing the ‘Intermediate’ Gray Area:

ESC uses scores like sPESI and biomarkers to split intermediate patients into low and high buckets.
AHA/ACC creates distinct separations (like Category D for incipient failure vs. Category C) to catch subtle patient deterioration much earlier.

Advanced Therapies and Interventions:

The A–E spectrum gives interventionalists, cardiologists, and PERTs much sharper guidance on when to escalate from standard anticoagulation to catheter-directed therapies or mechanical thrombectomy before a patient crashes.

Both guidelines share the same ultimate goals—rapid risk stratification and preventing mortality—but the shift toward a physiological, letter-graded scale represents a major step forward in precision medicine.

What has been your experience transitioning to the newer risk models in clinical practice?”

Stay updated with Hemostasis Today.